MXPA01011347A - Portador de farmaco producido a partir de conjugados de matriz lipida-farmaco (particula lak) para la aplicacion controlada de un agente activo. - Google Patents

Portador de farmaco producido a partir de conjugados de matriz lipida-farmaco (particula lak) para la aplicacion controlada de un agente activo.

Info

Publication number
MXPA01011347A
MXPA01011347A MXPA01011347A MXPA01011347A MXPA01011347A MX PA01011347 A MXPA01011347 A MX PA01011347A MX PA01011347 A MXPA01011347 A MX PA01011347A MX PA01011347 A MXPA01011347 A MX PA01011347A MX PA01011347 A MXPA01011347 A MX PA01011347A
Authority
MX
Mexico
Prior art keywords
medicament
conjugates
produced
lipid
active agent
Prior art date
Application number
MXPA01011347A
Other languages
English (en)
Inventor
Rainer Helmut Mueller
Original Assignee
Pharmasol Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE19920908A external-priority patent/DE19920908A1/de
Priority claimed from DE19964085A external-priority patent/DE19964085A1/de
Application filed by Pharmasol Gmbh filed Critical Pharmasol Gmbh
Publication of MXPA01011347A publication Critical patent/MXPA01011347A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/554—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being a steroid plant sterol, glycyrrhetic acid, enoxolone or bile acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/543—Lipids, e.g. triglycerides; Polyamines, e.g. spermine or spermidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Botany (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La invencion se refiere a portadores en particulas para agentes activos que a la temperatura ambiente (20°C) se encuentran en un estado agregado solido, consistente de un conjugado lipido-farmaco puro (LAK) o una mezcla de varios LAK como matriz de particulas, consistiendo el enlace en el LAK de enlaces covalentes, interacciones electrostaticas, momentos dipolares, fuerzas de dispersion, interacciones ionicas, puentes de hidrogeno y/o interacciones hidrofobicas.
MXPA01011347A 1999-05-07 2000-05-08 Portador de farmaco producido a partir de conjugados de matriz lipida-farmaco (particula lak) para la aplicacion controlada de un agente activo. MXPA01011347A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE19920908A DE19920908A1 (de) 1999-05-07 1999-05-07 Arzneistoffträger zur kontrollierten Wirkstoffapplikation hergestellt aus Lipidmatrix-Arzneistoffkonjugaten (LAK-Partikel)
DE19964085A DE19964085A1 (de) 1999-12-27 1999-12-27 Arzneistoffträgr zur kontrollierten Wirkstoffapplikation hergestellt aus Lipidmatrix-Arzneistoffkonjugaten (LAK-Partikel)
PCT/EP2000/004111 WO2000067800A2 (de) 1999-05-07 2000-05-08 Arzneistoffträger zur kontrollierten wirkstoffapplikation hergestellt aus lipidmatrix-arzneistoff-konjugaten (lak-partikel)

Publications (1)

Publication Number Publication Date
MXPA01011347A true MXPA01011347A (es) 2004-06-03

Family

ID=26053253

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA01011347A MXPA01011347A (es) 1999-05-07 2000-05-08 Portador de farmaco producido a partir de conjugados de matriz lipida-farmaco (particula lak) para la aplicacion controlada de un agente activo.

Country Status (11)

Country Link
US (1) US6770299B1 (es)
EP (1) EP1176984B1 (es)
JP (1) JP2002544177A (es)
KR (1) KR20020012215A (es)
AU (1) AU4563100A (es)
BR (1) BR0010356A (es)
CA (1) CA2372461A1 (es)
DE (1) DE50013950D1 (es)
MX (1) MXPA01011347A (es)
TR (1) TR200103187T2 (es)
WO (1) WO2000067800A2 (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007509981A (ja) * 2003-10-31 2007-04-19 テバ ファーマシューティカル インダストリーズ リミティド 薬物デリバリー用ナノ粒子
EP1698329A4 (en) * 2003-12-24 2009-10-28 Ltt Bio Pharma Co Ltd PHARMACEUTICAL NANOTEILS, METHOD FOR THE PRODUCTION THEREOF AND PARENTERALLY APPLIED PRODUCT FROM NANOTEILES
US7282194B2 (en) * 2004-10-05 2007-10-16 Gp Medical, Inc. Nanoparticles for protein drug delivery
US20070254037A1 (en) * 2004-12-15 2007-11-01 Youri Popowski Methods and Compositions for the Treatment of Cell Proliferation
EP1674081A1 (de) * 2004-12-23 2006-06-28 KTB Tumorforschungsgesellschaft mbH Herstellung von lipidbasierten Nanopartikeln unter Einsatz einer dualen asymmetrischen Zentrifuge
US9114077B2 (en) 2006-11-17 2015-08-25 Abbvie Deutschland Gmbh & Co Kg Nanocrystals for use in topical cosmetic formulations and method of production thereof
GB0623838D0 (en) 2006-11-29 2007-01-10 Malvern Cosmeceutics Ltd Novel compositions
US20090053268A1 (en) * 2007-08-22 2009-02-26 Depablo Juan J Nanoparticle modified lubricants and waxes with enhanced properties
US20090061009A1 (en) * 2007-08-29 2009-03-05 Joseph Schwarz Composition and Method of Treatment of Bacterial Infections
EP2393472B1 (en) 2008-12-05 2019-06-05 NanoMed Holdings Pty Ltd Amphiphile prodrugs
EP2229936B1 (en) * 2009-03-09 2015-05-06 PharmaSol GmbH Nanonized testosterone formulations for improved bioavailability
WO2012059936A1 (en) 2010-11-03 2012-05-10 Padma Venkitachalam Devarajan Pharmaceutical compositions for colloidal drug delivery
CN104127387A (zh) * 2014-02-21 2014-11-05 杭州长典医药科技有限公司 奥美拉唑钠特种超细粉体冻干制剂及其制备方法
BE1023491B1 (nl) * 2015-10-06 2017-04-06 Nutri-Ad International Nv Voedingsadditief voor gevogelte
AU2020245715A1 (en) * 2019-03-22 2021-08-19 Integrated Nanotherapeutics Inc. Lipid conjugate prepared from scaffold moiety

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5543390A (en) * 1990-11-01 1996-08-06 State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education, Acting For And On Behalf Of The Oregon Health Sciences University Covalent microparticle-drug conjugates for biological targeting
US5554728A (en) * 1991-07-23 1996-09-10 Nexstar Pharmaceuticals, Inc. Lipid conjugates of therapeutic peptides and protease inhibitors
DE4440337A1 (de) * 1994-11-11 1996-05-15 Dds Drug Delivery Services Ges Pharmazeutische Nanosuspensionen zur Arzneistoffapplikation als Systeme mit erhöhter Sättigungslöslichkeit und Lösungsgeschwindigkeit
US5907030A (en) * 1995-01-25 1999-05-25 University Of Southern California Method and compositions for lipidization of hydrophilic molecules
DE19745950A1 (de) * 1997-10-17 1999-04-22 Dds Drug Delivery Service Ges Arzneistoffträgerpartikel für die gewebespezifische Arzneistoffapplikation

Also Published As

Publication number Publication date
CA2372461A1 (en) 2000-11-16
WO2000067800A2 (de) 2000-11-16
TR200103187T2 (tr) 2002-04-22
EP1176984B1 (de) 2007-01-10
KR20020012215A (ko) 2002-02-15
EP1176984A2 (de) 2002-02-06
BR0010356A (pt) 2002-02-13
WO2000067800A3 (de) 2001-05-10
JP2002544177A (ja) 2002-12-24
DE50013950D1 (de) 2007-02-22
US6770299B1 (en) 2004-08-03
AU4563100A (en) 2000-11-21

Similar Documents

Publication Publication Date Title
MXPA01011347A (es) Portador de farmaco producido a partir de conjugados de matriz lipida-farmaco (particula lak) para la aplicacion controlada de un agente activo.
SE9101665L (sv) Laekemedelsbaerare
CA2278541A1 (en) Pharmaceutical preparations and methods for their regional administration
BR9810945A (pt) Formulações de agentes farmacológicos, métodos para sua preparação e métodos para uso das mesmas
CA2267498A1 (en) Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof
WO2000071079A3 (en) Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof
BR0012624A (pt) Métodos para a preparação de agentes terapêuticos envolvidos por lipìdeos
MX9702357A (es) Microparticulas secadas por aspersion como vehiculos terapeuticos.
WO2000045792A8 (en) Hydrogel particle formulations
WO2003022252A3 (en) Combinatorial type (several vehicles within a housing) controlled release drug delivery device
WO2001035932A3 (en) Sustained drug delivery from structural matrices
WO2001028525A3 (en) Method of producing sub-micron particles of biologically active agents
DE3579069D1 (de) Lipidnanopellets als traegersystem fuer arzneimittel zur peroralen anwendung.
EP1355634A2 (en) Sn-38 lipid complexes and methods of use
PT954282E (pt) Preparacao de particulas para inalacao
EP2014286A3 (en) Cremophor free epothilone particles coated with protein for treating cancer
García-Fernández et al. Targeting inflammasome by the inhibition of caspase-1 activity using capped mesoporous silica nanoparticles
WO2003087757A3 (en) Particle-bound human immunodeficiency virus envelope clycoproteins and related compositions and methods
CA2210823A1 (en) Pharmaceutical compositions comprising lactobacilli suitable for trans-mucosal administration
NZ513981A (en) Delivery of microparticle formulations using needleless syringe device for sustained-release of bioactive compounds
DK0519950T3 (da) Præparat
SG165156A1 (en) Novel formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof
KR100624499B1 (ko) 나노졸을 함유한 의약제제
JPH0617316B2 (ja) 経皮吸収製剤
AU2503900A (en) Sulfated phosphatidylinositols, their preparation and use